OGN at a glance
Organon & Co (OGN, SEC CIK 1821825) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on July 31, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Organon & Co (OGN) reported revenue of $6.2 billion (down 2.9% from FY2024) and net income of $187.0 million. Diluted EPS was $0.72.
- As of June 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Organon & Co (OGN) shares worth $1.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Drinane Juliana Papa on August 5, 2026 of 14,761 shares at $13.57 per share.
- In the last 90 days, OGN insiders reported 0 open-market purchases ($0) and 1 open-market sale ($200K) on Form 4, a net sale of $200K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.2B
- −2.9% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$200K
- 13F holders
- 37 funds
- $1.3B · −2 vs prior quarter
- Latest 10-Q
- Jul 31, 2026
- Quarterly report
SignalX for OGN
Don't miss the next OGN filing
- Alerts as it files. A push when OGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OGN, by share count.
- Ask anything. An AI agent that reads every OGN filing and answers with sources.
OGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Arjona Ferreira Juan Camilo | F | Aug 11, 2026 | 4,134 | $13.62 |
| Arjona Ferreira Juan Camilo | M | Aug 11, 2026 | 11,519 | - |
| Arjona Ferreira Juan Camilo | M | Aug 11, 2026 | 11,519 | - |
| Drinane Juliana Papa | Sell | Aug 5, 2026 | 14,761 | $13.57 |
| Sharp Shalini | A | Jun 12, 2026 | 17,857.143 | $13.44 |
| Gayle Helene D | A | Jun 12, 2026 | 17,857.143 | $13.44 |
| Patton Cynthia M | A | Jun 12, 2026 | 17,857.143 | $13.44 |
| Sequeira Ramona | A | Jun 12, 2026 | 17,857.143 | $13.44 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $6.3B | $6.4B | $6.2B |
| Gross Profit | $3.7B | $3.7B | $3.3B |
| Net Income | $1.0B | $864.0M | $187.0M |
| Gross Margin | 59.8% | 58.0% | 53.3% |
| Net Margin | 16.3% | 13.5% | 3.0% |
| Balance Sheet | |||
| Total Assets | - | $13.1B | $12.9B |
| Equity | - | $472.0M | $752.0M |
| ROE | - | 183.1% | 24.9% |
| Per Share | |||
| EPS | $3.99 | $3.33 | $0.72 |
| Cash Flow | |||
| Operating CF | - | $939.0M | $700.0M |
| CapEx | - | $175.0M | $162.0M |
Source: XBRL data in Organon & Co (OGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate OGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 37 | $1.33B |
| Q1 2026 | 39 | $699.0M |
| Q4 2025 | 34 | $837.3M |
| Q3 2025 | 35 | $1.17B |
| Q2 2025 | 36 | $1.15B |
| Q1 2025 | 30 | $1.06B |
| Q4 2024 | 28 | $875.9M |
| Q3 2024 | 26 | $551.0M |
- Goldman Sachs Group+3.59M (+224%)
- BlackRock+339.8K (+1%)
- Vanguard Capital Management LLC+172.8K (+1%)
- Northern Trust+166.4K (+9%)
- Franklin Resources+125.3K (+44%)
- Vanguard Portfolio Management LLC−6.71M (-31%)
- Millennium Management−3.34M (-49%)
- Two Sigma Investments−2.90M (-92%)
- AQR Capital Management−2.21M (-64%)
- D.E. Shaw & Co−1.93M (-73%)
- Blackstone Group+105.5K
- Bridgewater Associates LP−594.5K
- Mangrove Partners−73.2K
- Truist Financial−10.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 265 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OGN SEC filings: frequently asked questions
Are OGN insiders buying or selling?
In the last 90 days, Organon & Co (OGN) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $200,307 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OGN stock?
As of June 30, 2026, the largest Organon & Co (OGN) holders among the 13F filers tracked by SignalX were BlackRock ($434.0 million), Vanguard Portfolio Management LLC ($204.9 million), Vanguard Capital Management LLC ($161.3 million), State Street Corp ($130.8 million), Goldman Sachs Group ($70.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Organon & Co (OGN) reported revenue of $6.2 billion (down 2.9% from FY2024) and net income of $187.0 million. Diluted EPS was $0.72. The figures come from the XBRL data in the 10-K.
What are the latest OGN SEC filings?
Organon & Co (OGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on July 31, 2026 and a Form 4 insider filing on August 12, 2026.
What is OGN's SEC CIK number?
Organon & Co (OGN)'s SEC Central Index Key (CIK) is 1821825. EDGAR lists every OGN filing under that number.
Ask anything about OGN
The research agent reads OGN's filings, financials, insider trades and 13F holders, then answers with sources.